Novozymes, Biotalys successfully conclude feasibility study for novel biofungicide Evoca
Evoca helps sustainably control economically important fungal diseases such as Botrytis and powdery mildew in fruits and vegetables.
Novozymes and Biotalys, an Agricultural Technology (AgTech) company protecting crops and food with protein-based biocontrol solutions have announced the successful outcome of the feasibility study for Evoca™*, Biotalys’ first proprietary biocontrol product candidate.
Novozymes obtained proof of concept for a new manufacturing process that offers potential significant cost of goods and scaling advantages, thereby broadening the commercial potential of Evoca as a novel biofungicide.
Evoca is Biotalys’ first innovative protein-based biofungicide developed on the company’s AGROBODY Foundry™ platform which platform allows Biotalys to discover and develop novel biological food protection solutions that combine high efficacy, consistency and safety, with new modes of action to fight resistance.
Evoca helps sustainably control economically important fungal diseases such as Botrytis and powdery mildew in fruits and vegetables.
“Thanks to its leading protein fermentation expertise, Novozymes has been able to further increase the efficiency of production for Evoca,” said Patrice Sellès, the CEO of Biotalys. “We will now work on a deeper partnership with Novozymes and explore strategic supply and commercialization agreements for the future generation of Evoca while continuing our ongoing internal development activities.”
“Now one step closer to large-scale production, Biotalys and Novozymes have successfully collaborated to provide the industry and growers new ways to safely control damaging pests and diseases and deliver our shared goal of providing highly effective solutions so growers can sustainably feed the world.” Noted Thomas Batchelor, Vice President, Agriculture Marketing and Strategy of Novozymes.
Evoca helps sustainably control economically important fungal